Pacira Biosciences Inc. (NASDAQ:PCRX) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET

Company Participants

Susan Mesco - Head of Investor Relations
Frank Lee - Chief Executive Officer
Shawn Cross - Chief Financial Officer
Kristen Williams - Chief Administrative Officer
Lauren Riker - Senior Vice President Finance
Jonathan Slonin - Chief Medical Officer

Conference Call Participants

Oren Livnat - H.C. Wainwright
David Amsellem - Piper Sandler
Les Sulewski - Truist Securities

Operator

Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all participants are listen only mode. After the speaker's presentation, there'll be a question-and-answer session. Instructions will be given at that time. As a reminder, this call may be recorded.

I would like to turn the call over to Susan Mesco, Head of Investor Relations. Please go ahead.

Susan Mesco

Thank you, and good afternoon, everyone. Welcome to today's conference call to discuss our third quarter 2024 financial results. Joining me are Frank Lee, Chief Executive Officer; and Shawn Cross, Chief Financial Officer; Kristen Williams, Chief Administrative Officer; Lauren Riker, Senior Vice President Finance; and Jonathan Slonin, Chief Medical Officer are also here for today's question-and-answer session.

Before we begin, let me remind you that this call will include forward looking statements subject to the safe harbor provisions of federal securities laws. Such statements represent our judgment as of today and may involve risks and uncertainties, which may cause our actual results, performance, or achievements to differ materially. For information concerning risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or the Pacira website.

Lastly, as a reminder, we will be discussing non-GAAP financial measures on today's call. A description of these metrics along with our reconciliation to GAAP can be found in the news release we issued earlier this afternoon.

With that, I will now turn the call over to Frank Lee.

Frank Lee

Thank you, Susan, and good afternoon, everyone. As you know, our top priority in 2024 is to ensure that as an organization, we're well-positioned to deliver accelerated growth in 2025 and beyond. Since our last call, we've continued to make important progress in three key areas. First, we're now aligned and committed to a refreshed clear mission to deliver innovative non-opioid pain fair to transform the lives of patients.

It's a straightforward, yet compelling mission that personally resonates with me and our Pacira employees. Underpinning our mission are three guiding principles that we uphold every day. Keep the patient at the center, follow the science, and treat our people well. Second, we've completed a comprehensive portfolio review and defined a growth-oriented long-term plan and therapeutic area strategy focused on musculoskeletal pain and adjacencies. These are all significant and growing markets of high unmet need that are poised for innovation. Our portfolio of products and expertise in the space leaves us well-positioned to drive innovation and create value. Third, we've established a foundation for a modernized best practice, commercial, market access, and medical powerhouse. In parallel, we'll continue to advance our commercial initiatives as we lay the groundwork for expanded EXPAREL utilization ahead of the implementation of NOPAIN.